| (Values in U.S. Thousands) | Dec, 2017 | Dec, 2016 | Dec, 2015 | Jan, 2026 | Jan, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -42,430 | -33,620 | -24,980 | 0 | 0 |
| Net Income Growth | -26.20% | -34.59% | unch | unch | unch |
Armo Biosciences Inc. (ARMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ARMO Biosciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company's platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects which induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8 T cells in cancer patients. Its product pipeline includes AM0001, an anti-PD-1 checkpoint inhibitor; AM0003 an anti-LAG-3 checkpoint inhibitor; AM0015 a form of recombinant human Interleukin-15 cytokine and AM0012 a form of recombinant human Interleukin-12 cytokine. ARMO Biosciences, Inc. is based in REDWOOD CITY, United States.
Fiscal Year End Date: 12/31